Skip to content

US · MAZE · BIOTECHNOLOGY

Maze Therapeutics, Inc. (MAZE) intrinsic value and stock valuation

$31.37as of 2026-11-21 · Mkt cap 1.54B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Maze Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values MAZE with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MAZE’s statements →

Maze Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology South San Francisco, CA 94080 mazetx.com

How the business is doing

Fiscal 2022–2025, USD

Revenue
$0.00
20222025
Net income
-$-131.12M
20222025
Free cash flow
-$-112.73M
20222025
Total equity
$355M
20222025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2022–2025, USD
2025202420232022
Revenue$0.00$167.5M$0.00$0.00
Operating income-$-142.9M$57.6M-$-98.55M-$-111.03M
Net income-$-131.12M$52.2M-$-100.42M-$-114.94M
EPSd-$-3.05M$1.19M-$-2.29M-$-2.63M
Operating cash flow-$-111.94M$76M-$-86.83M-$-99.2M
Capital expenditure-$-790K-$-1.15M-$-440K-$-1.97M
Free cash flow-$-112.73M$74.8M-$-87.27M-$-101.17M
Total assets$397.1M$240.5M$71.5M$150M
Total debt$23.3M$26.6M$49.6M$32.1M
Net debt-$-165.94M-$-170.18M$20.5M-$-67.86M
Total equity$355M$196.9M$10.1M$101.4M
Cash and short-term investments$341.9M$196.8M$29.2M$99.9M
Income statement
2025202420232022
Revenue$0.00$167.5M$0.00$0.00
Cost of revenue$2.4M$0.00$0.00$0.00
Gross profit-$-2.4M$167.5M$0.00$0.00
Research and development expenses$108.5M$83.5M$73.9M$88.2M
Selling, general and administrative expenses$34.5M$26.4M$24.6M$22.8M
Other expenses-$-2.4M$0.00$0.00$0.00
Operating expenses$140.5M$109.9M$98.6M$111M
Cost and expenses$142.9M$109.9M$98.6M$111M
Interest income$11.8M$4.65M$1.97M$2.03M
Interest expense$0.00$0.00$0.00$0.00
Depreciation and amortization$2.4M$3.3M$4.09M$3.82M
Ebitda-$-128.72M$56.7M-$-96.33M-$-111.12M
Operating income-$-142.9M$57.6M-$-98.55M-$-111.03M
Total other income/expenses, net$11.8M-$-4.18M-$-1.86M-$-3.91M
Income before tax-$-131.12M$53.4M-$-100.42M-$-114.94M
Income tax expense$0.00$1.17M$0.00$0.00
Net income-$-131.12M$52.2M-$-100.42M-$-114.94M
Weighted average shares outstanding$43M$43.8M$43.8M$43.8M
Weighted average diluted shares outstanding$43M$43.8M$43.8M$43.8M
Balance sheet
2025202420232022
Cash and short-term investments$341.9M$196.8M$29.2M$99.9M
Net receivables$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00
Total current assets$349.7M$201.7M$34.1M$106.2M
Property, plant and equipment, net$25.2M$29.9M$35M$41.2M
Goodwill and intangible assets$0.00$0.00$0.00$0.00
Long-term investments$18.1M$1.09M$1.09M$1.21M
Total non-current assets$47.4M$38.9M$37.4M$43.8M
Total assets$397.1M$240.5M$71.5M$150M
Accounts payable$1.79M$1.94M$2.02M$1.58M
Short-term debt$4.79M$4.63M$4.49M$4.32M
Deferred revenue$0.00$0.00$0.00$0.00
Total current liabilities$22.6M$20.7M$16.3M$20.8M
Long-term debt$18.5M$22M$45.1M$27.7M
Deferred revenue, non-current$0.00$0.00$0.00$0.00
Total non-current liabilities$19.6M$23M$45.1M$27.7M
Capital lease obligations$23.3M$26.6M$29.5M$32.1M
Total liabilities$42.2M$43.6M$61.5M$48.5M
Common stock$50K$0.00$20K$20K
Retained earnings-$-489.55M-$-358.43M-$-395.69M-$-295.27M
Accumulated other comprehensive income (loss)$110K$0.00$0.00$0.00
Total equity$355M$196.9M$10.1M$101.4M
Total investments$170.8M$1.09M$1.09M$1.21M
Total debt$23.3M$26.6M$49.6M$32.1M
Net debt-$-165.94M-$-170.18M$20.5M-$-67.86M
Cash flow statement
2025202420232022
Net income-$-131.12M$52.2M-$-100.42M-$-114.94M
Depreciation and amortization$2.4M$3.3M$4.09M$3.82M
Stock-based compensation$16.4M$9.65M$8.75M$6.74M
Change in working capital-$-2.27M-$-1.52M-$-6.32M-$-3.24M
Accounts receivable$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00
Accounts payable-$-30K-$-200K$400K-$-3.78M
Net cash provided by operating activities-$-111.94M$76M-$-86.83M-$-99.2M
Investments in property, plant and equipment-$-790K-$-1.15M-$-440K-$-1.97M
Acquisitions, net$0.00$0.00$0.00-$-1.2M
Net cash used for investing activities-$-170.96M-$-1.15M-$-440K-$-3.17M
Common stock issued$275.8M$68.4M$210K$1.73M
Common stock repurchased$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00
Net cash used for financing activities$275.3M$92.9M$16.4M$1.73M
Net change in cash-$-7.57M$167.7M-$-70.88M-$-100.64M
Cash at end of period$190.3M$197.9M$30.3M$101.1M
Operating cash flow-$-111.94M$76M-$-86.83M-$-99.2M
Capital expenditure-$-790K-$-1.15M-$-440K-$-1.97M
Free cash flow-$-112.73M$74.8M-$-87.27M-$-101.17M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Maze Therapeutics, Inc.

        Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

        CEO
        Jason Coloma
        Employees
        141
        Beta
        2.14

        Explore

        Frequently asked questions

        What is the intrinsic value of Maze Therapeutics, Inc. (MAZE)?

        InvestorsCraft does not currently publish an intrinsic value for MAZE. How the IC value is calculated.

        Is MAZE undervalued?

        InvestorsCraft does not publish an undervaluation signal for MAZE at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.